Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A DB, Placebo-Controlled, Two-Arm Parallel-Group, Phase 3 RCT to Investigate the Efficacy and Safety of Recombinant Human Alkaline Phosphatase for Treatment of Patients With SA-AKI

Next Previous
Trial Profile

A DB, Placebo-Controlled, Two-Arm Parallel-Group, Phase 3 RCT to Investigate the Efficacy and Safety of Recombinant Human Alkaline Phosphatase for Treatment of Patients With SA-AKI

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 16 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ilofotase alfa (Primary)
  • Indications Acute kidney injury; Renal failure; Sepsis
  • Focus Registrational; Therapeutic Use
  • Acronyms REVIVAL
  • Sponsors AM-Pharma

    • Most Recent Events

    • 01 Jan 2024 Results for safety and efficacy of Ilofotase-alfa, published in the Intensive Care Medicine
    • 09 Mar 2023 According to AM-Pharma Media Release, Professor Peter Pickkers, M.D., Ph.D., principal investigator of the this study, will present data at two upcoming scientific conferences namely - 42nd International Symposium on Intensive Care & Emergency Medicines (ISICEM) on March 21st in Brussels, Belgium and at the 28th International Conference on Advances in Critical Care Nephrology AKI & CRRT on March 29th in San Diego, CA, USA.
    • 09 Mar 2023 Results presented in an AM-Pharma Media Release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top